AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is conducting a real-world study titled ‘Early Treatment of Heart Failure: a Non-interventional Study Program of Patients With Heart Failure and Initiated on Dapagliflozin (EVOLUTION-HF DEallEF)’ in Germany. The study aims to evaluate the usage of dapagliflozin in patients with heart failure, focusing on treatment patterns, symptoms, and the impact on health-related quality of life and healthcare utilization.
The intervention being tested is dapagliflozin, a medication recently approved by the European Commission for heart failure treatment, regardless of ejection fraction and diabetes status. It is intended to improve heart failure symptoms and patients’ quality of life.
This observational cohort study is designed to prospectively collect data from patients with various ejection fractions receiving dapagliflozin. The study does not involve randomization or masking, as it aims to gather real-world evidence.
The study began on April 25, 2024, with the latest update submitted on August 13, 2025. These dates are crucial as they mark the progress and currency of the study, indicating ongoing data collection and analysis.
The study’s findings could influence AstraZeneca’s stock performance by potentially enhancing investor confidence in the company’s cardiovascular portfolio. As dapagliflozin is already approved, the real-world data could solidify its market position against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.